These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8781780)
1. P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. Kharasch ED; Hankins DC Drug Metab Dispos; 1996 Jun; 24(6):649-54. PubMed ID: 8781780 [TBL] [Abstract][Full Text] [Related]
2. Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). Altuntas TG; Park SB; Kharasch ED Chem Res Toxicol; 2004 Mar; 17(3):435-45. PubMed ID: 15025515 [TBL] [Abstract][Full Text] [Related]
3. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151 [TBL] [Abstract][Full Text] [Related]
4. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro. Altuntas TG; Kharasch ED Toxicol Appl Pharmacol; 2001 Dec; 177(2):85-93. PubMed ID: 11740907 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. Kharasch ED; Jubert C; Spracklin DK; Hoffman GM Toxicol Appl Pharmacol; 1999 Oct; 160(1):49-59. PubMed ID: 10502502 [TBL] [Abstract][Full Text] [Related]
6. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. Spracklin DK; Kharasch ED Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812 [TBL] [Abstract][Full Text] [Related]
7. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism. Gul Altuntas T; Kharasch ED Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. Altuntas TG; Zager RA; Kharasch ED Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716 [TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. Kharasch ED; Schroeder JL; Bammler T; Beyer R; Srinouanprachanh S Toxicol Sci; 2006 Apr; 90(2):419-31. PubMed ID: 16384817 [TBL] [Abstract][Full Text] [Related]
10. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Kharasch ED; Thummel KE Anesthesiology; 1993 Oct; 79(4):795-807. PubMed ID: 8214760 [TBL] [Abstract][Full Text] [Related]
11. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. Jin L; Davis MR; Kharasch ED; Doss GA; Baillie TA Chem Res Toxicol; 1996 Mar; 9(2):555-61. PubMed ID: 8839062 [TBL] [Abstract][Full Text] [Related]
12. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Kharasch ED; Hankins DC; Thummel KE Anesthesiology; 1995 Mar; 82(3):689-99. PubMed ID: 7879937 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes: a role for cytochrome P4502E1 at low substrate concentrations. Madan A; Parkinson A Drug Metab Dispos; 1996 Dec; 24(12):1307-13. PubMed ID: 8971135 [TBL] [Abstract][Full Text] [Related]
14. Renal toxicity with sevoflurane: a storm in a teacup? Gentz BA; Malan TP Drugs; 2001; 61(15):2155-62. PubMed ID: 11772127 [TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. Spracklin DK; Hankins DC; Fisher JM; Thummel KE; Kharasch ED J Pharmacol Exp Ther; 1997 Apr; 281(1):400-11. PubMed ID: 9103523 [TBL] [Abstract][Full Text] [Related]
16. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Kharasch ED; Frink EJ; Zager R; Bowdle TA; Artru A; Nogami WM Anesthesiology; 1997 Jun; 86(6):1238-53. PubMed ID: 9197292 [TBL] [Abstract][Full Text] [Related]
17. Effect of phenytoin (DPH) treatment on methoxyflurane metabolism in rats. Caughey GH; Rice SA; Kosek JC; Mazze RI J Pharmacol Exp Ther; 1979 Aug; 210(2):180-5. PubMed ID: 458627 [TBL] [Abstract][Full Text] [Related]
18. Oxidative defluorination of 1,1,1,2-tetrafluoroethane by rat liver microsomes. Olson MJ; Reidy CA; Johnson JT; Pederson TC Drug Metab Dispos; 1990; 18(6):992-8. PubMed ID: 1981550 [TBL] [Abstract][Full Text] [Related]
19. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Thummel KE; Kharasch ED; Podoll T; Kunze K Drug Metab Dispos; 1993; 21(2):350-7. PubMed ID: 8097708 [TBL] [Abstract][Full Text] [Related]
20. Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following ethanol consumption. Rice SA; Dooley JR; Mazze RI Anesthesiology; 1983 Mar; 58(3):237-41. PubMed ID: 6829959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]